Oct 5, 2026 7:00 am EDT Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Sep 24, 2026 4:05 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Sep 9, 2026 7:00 am EDT Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Jun 17, 2026 7:00 am EDT Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Jun 4, 2026 7:30 am EDT Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Jun 2, 2026 7:00 am EDT Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
May 12, 2026 4:05 pm EDT Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
